149 related articles for article (PubMed ID: 38683590)
1. L-type Amino Acid Transporter 1 as a Therapeutic Target in Pancreatic Cancer.
Norrsell R; Bauden M; Andersson R; Ansari D
Cancer Control; 2024; 31():10732748241251583. PubMed ID: 38683590
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.
Kaira K; Sunose Y; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Segawa A; Furuya M; Mori M; Oyama T; Takeyoshi I
Br J Cancer; 2012 Aug; 107(4):632-8. PubMed ID: 22805328
[TBL] [Abstract][Full Text] [Related]
3. The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer.
Häfliger P; Charles RP
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100853
[TBL] [Abstract][Full Text] [Related]
4. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
[TBL] [Abstract][Full Text] [Related]
5. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
Yanagisawa N; Ichinoe M; Mikami T; Nakada N; Hana K; Koizumi W; Endou H; Okayasu I
J Clin Pathol; 2012 Nov; 65(11):1019-23. PubMed ID: 22813728
[TBL] [Abstract][Full Text] [Related]
6. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.
Ma Y; Okuda S; Okanishi H; Xu M; Jin C; Endou H; Ohgaki R; Kanai Y
J Pharmacol Sci; 2024 May; 155(1):14-20. PubMed ID: 38553134
[TBL] [Abstract][Full Text] [Related]
8. c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells.
Hayashi K; Jutabha P; Endou H; Anzai N
Oncol Rep; 2012 Sep; 28(3):862-6. PubMed ID: 22736142
[TBL] [Abstract][Full Text] [Related]
9. L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy.
Hayashi K; Anzai N
J Pharmacol Sci; 2022 Jan; 148(1):31-40. PubMed ID: 34924127
[TBL] [Abstract][Full Text] [Related]
10. The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells.
Kim CH; Park KJ; Park JR; Kanai Y; Endou H; Park JC; Kim DK
Anticancer Res; 2006; 26(4B):2943-8. PubMed ID: 16886618
[TBL] [Abstract][Full Text] [Related]
11. [Drug Discovery Targeting an Amino Acid Transporter for Diagnosis and Therapy].
Wiriyasermkul P; Moriyama S; Kongpracha P; Nagamori S
Yakugaku Zasshi; 2021; 141(4):501-510. PubMed ID: 33790117
[TBL] [Abstract][Full Text] [Related]
12. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
Kanai Y
Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
[TBL] [Abstract][Full Text] [Related]
13. The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.
Lu X
Curr Cancer Drug Targets; 2019; 19(11):863-876. PubMed ID: 31376820
[TBL] [Abstract][Full Text] [Related]
14. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
15. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
16. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
Kärkkäinen J; Gynther M; Kokkola T; Petsalo A; Auriola S; Lahtela-Kakkonen M; Laine K; Rautio J; Huttunen KM
Int J Pharm; 2018 Jun; 544(1):91-99. PubMed ID: 29669256
[TBL] [Abstract][Full Text] [Related]
17. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of L-Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta-Analysis.
Zhang C; Xu J; Xue S; Ye J
Mol Diagn Ther; 2020 Oct; 24(5):523-536. PubMed ID: 32410110
[TBL] [Abstract][Full Text] [Related]
19. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.
Jin SE; Jin HE; Hong SS
Expert Opin Ther Targets; 2015; 19(10):1319-37. PubMed ID: 25968633
[TBL] [Abstract][Full Text] [Related]
20. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]